^
Association details:
| Biomarker: | CCNE1 overexpression |
|---|---|
| Cancer: | Hormone Receptor Positive Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer
Excerpt:
Palbociclib efficacy was lower in patients with high versus low cyclin E1 (CCNE1) mRNA expression (median PFS: palbociclib arm, 7.6 v 14.1 months; placebo arm, 4.0 v 4.8 months, respectively; interaction P unadjusted = .00238; false discovery rate-adjusted P = .0238).
DOI:
10.1200/JCO.18.00925
Trial ID:
Source:
Title:
Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
Excerpt:
CONTRADICTING EVIDENCE: Addition of palbociclib to fulvestrant demonstrated efficacy in all biomarker groups, although high CCNE1 mRNA expression was associated with relative resistance to palbociclib....In an exploratory subtype-specific analysis, the effect of CCNE1 mRNA as a continuous variable on improvement in PFS from adding palbociclib to fulvestrant was observed in both luminal B and nonluminal subtypes (interaction P = .03 and .007, respectively) but not in the luminal A subtype (interaction P = .49).
Secondary therapy:
fulvestrant
DOI:
10.1158/1078-0432.CCR-15-3036
Trial ID:
